HPV vaccination and cervical cancer deaths: from incidence reduction to mortality prevention

Abstract

Persistent infection with carcinogenic human papillomavirus (HPV) types causes the great majority of cervical cancers. For more than a decade, randomized trials, surveillance studies, and national registry analyses have demonstrated reductions in vaccine-type HPV infection, high-grade cervical precancer, and invasive cervical cancer following HPV vaccination. Direct evidence regarding cervical cancer mortality has emerged more recently because cohorts vaccinated in early adolescence first had to reach ages at which cervical cancer deaths became observable. A 2026 population-based analysis from England reported no cervical cancer deaths among the most highly vaccinated women aged 20 to 24 years during 2020 to 2024, with substantial mortality reductions also observed in older vaccinated cohorts, although uncertainty increased with age. This narrative review synthesizes the biological and epidemiologic evidence linking HPV vaccination to mortality prevention, critically appraises the England mortality study and its age-stratified findings, considers limitations related to cervical screening and the modeled counterfactual, and discusses implications for cervical cancer elimination, including relevance to Qatar and the wider Eastern Mediterranean region. Current evidence supports early adolescent HPV vaccination as a central cancer-prevention intervention, while continued cervical screening, timely treatment, high and equitable vaccine coverage, and long-term surveillance remain essential. The available mortality evidence is compelling at the population-program level but should not be interpreted as an individual-level randomized estimate of vaccine effectiveness against cervical cancer death.

Keywords

Human papillomavirus / HPV vaccine / Cancer mortality / Cervical cancer elimination / Cervical cancer screening

References

[1] IARC Working Group on the Evaluation of Carcinogenic Risks to HumansHuman papillomaviruses, 2007, Lyon, France: International Agency for Research on Cancer

[2] Wei FX, Georges D, Man I, et al. Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature. Lancet, 2024, 40410451435444.

[3] Fernandes A, Viveros-Carreño D, Hoegl J, et al. Human papillomavirus-independent cervical cancer. Int J Gynecol Cancer, 2022, 32117.

[4] Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63. https://doi.org/10.3322/caac.21834.

[5] World Health OrganizationGlobal strategy to accelerate the elimination of cervical cancer as a public health problem, 2020, Geneva: World Health Organization

[6] World Health OrganizationHuman papillomavirus vaccines: WHO position paper, December 2022. Week Epidemiol Rec, 2022, 9751–52645672

[7] Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis, 2003, 2083385393.

[8] Rosenblum HG, Lewis RM, Gargano JW, et al. Declines in prevalence of human papillomavirus vaccine-type infection among females after introduction of vaccine—United States, 2003–2018. MMWR Morb Mortal Wkly Rep, 2003, 7012415420.

[9] Drolet M, Bénard É, Pérez N, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet, 2019, 39410197497509.

[10] Lei JY, Ploner A, Elfström KM, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med, 2020, 3831413401348.

[11] Kjaer SK, Dehlendorff C, Belmonte F, et al. Real-world effectiveness of human papillomavirus vaccination against cervical cancer. J Natl Cancer Inst, 2021, 1131013291335.

[12] Falcaro M, Castañon A, Ndlela B, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet, 2021, 3981031620842092.

[13] Falcaro M, Soldan K, Ndlela B, et al. Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study. BMJ, 2024, 385. e077341

[14] Palmer TJ, Kavanagh K, Cuschieri K, et al. Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and deprivation. J Natl Cancer Inst, 2024, 1166857865.

[15] Sasieni P, Falcaro M. Cervical cancer mortality trends following HPV vaccination in England, 2001–24: an analysis of population-based mortality data. Lancet, 2026, 40810550162168.

[16] NHS England Digital. Cervical screening programme, England—2023–2024. (2026–08–27)[2024–11–28]. https://digital.nhs.uk/data-and-information/publications/statistical/cervical-screening-annual/england-2023-24.

[17] Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med, 2015, 3728711723.

[18] Arbyn M, Bryant A, Beutels P, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev, 2018, 5. CD009069

[19] UK Health Security Agency. Human papillomavirus (HPV) vaccination coverage in adolescents in England: 2024 to 2025. London: UKHSA; 2026. (2026–8–27)[2026–01–29]. https://www.gov.uk/government/statistics/human-papillomavirus-hpv-vaccine-coverage-in-england-2024-to-2025.

[20] U.S. Centers for Disease Control and Prevention. Human papillomavirus (HPV) vaccine safety. (2026–8–27)[2025–03–06]. https://www.cdc.gov/vaccine-safety/vaccines/hpv.html.

[21] World Health Organization. Safety of HPV vaccines. (2026–8–27)[ 2017–07–14]. https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/human-papillomavirus-vaccines/safety.

[22] Troisi G, Gafer N, Alsawahli H, et al. Harnessing primary healthcare to reduce the burden of cervical cancer in the Eastern Mediterranean Region. BMJ Glob Health, 2025, 106e017622

[23] El-Zein M, Kassam P, Alhamlan F, et al. Toward cervical cancer prevention and elimination in the Eastern Mediterranean Region: current landscape and opportunities for evidence-based action. Prev Med, 2026, 208. 108549

[24] Ervik M, Laversanne M, Lam F, et al. Global Cancer Observatory: Cancer Today—Qatar fact sheet (2024 estimates, version 1.0). (2026–8–27)[2024–02–01]. https://gco.iarc.who.int/media/globocan/factsheets/populations/634-qatar-fact-sheet.pdf.

[25] Al Khaldi S, Tabche C, Atwan Z, et al. Knowledge and awareness of HPV vaccination uptake and recommendations in gulf cooperation council countries 2009–2025: a systematic review. Arch Public Heal, 2026, 84181.

[26] Cheema S, Abraham A, Maisonneuve P, et al. HPV infection and vaccination: a cross-sectional study of knowledge, perception, and attitude to vaccine uptake among university students in Qatar. BMC Public Health, 2024, 2412316

[27] Albayat SS, Mundodan JM, Elmardi K, et al. Knowledge, attitude, and practices regarding human papilloma virus vaccination among physicians in Qatar. Women Health (Lond), 2024, 20. 17455057241227360

[28] NHS England. NHS sets ambition to eliminate cervical cancer by 2040. (2026–8–27)[2023–11–15]. https://www.england.nhs.uk/2023/11/nhs-sets-ambition-to-eliminate-cervical-cancer-by-2040/.

Rights & permissions

The Author(s)